Spinomix develops fully automated and miniaturised systems enabling extraction, manipulation and detection of biochemical substances. The company uses two proprietary technologies: MagPhase, an automated sample preparation platform based on magnetic nanoparticles and microfluidics with disposable cartridges; and FibroTrap, a fibrinogen-based technology to separate targeted cells and molecules within routine sample collection tubes. Founded in 2004 and located at the Swiss Federal Institute of Technology of Lausanne (EPFL), Spinomix operates from Lausanne, Switzerland. The company closed a $3M Series A equity funding led by Debiopharm Group. Spinomix intends to use the funds to continue to develop its pipeline and to strengthen existing and new in vitro diagnostic industry collaborations. In conjunction with the funding, Thierry Mauvernay of Debiopharm joined the company’s board.

Total raised

$3M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2013